Positive Health Online

Krisztina Krempels MD is research fellow and medical consultant at HYD LLC for Cancer Research and Drug Development, Budapest, Hungary. She graduated as a medical doctor in 1991 from Semmelweis University Medical School Budapest, Hungary and worked in the neuroendocrine research team in the Department of Human Morphology and Developmental Biology at Semmelweis University in 1987. Dr Krempels was a postdoctoral fellow at the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland USA and in 1994 - 1996 worked in the fields of molecular biology, immunohistochemistry and mapping of receptor mRNAs. Since 2004 she has worked for the HYD LLC for Cancer Research and Drug Development in the proprietary procedure of deuterium depletion for the treatment and prevention of cancer. Her research area is the evaluation of the clinical benefits of deuterium depletion. She may be contacted via krempels@hyd.hu  www.hyd.hu/en

Ildikó Somlyai MSc is Senior Research Fellow at HYD LLC for Cancer Research and Drug Development, Budapest, Hungary. Her speciality is Cancer Research at the submolecular level. She graduated in biology in 1982 from University of Szeged, Hungary and worked in recombinant DNA technology at the Biological Research Centre of the Hungarian Academy of Sciences at Szeged, Hungary. From 1982 she worked for Gedeon Richter Plc. for 13 years until 1995. During her study and work in the pharmaceutical industry she gained experience in molecular biology, and transposon mutagenesis for industrial strain development. Since 1995 she works in cancer research, investigating the biological importance of naturally occurring deuterium and the various biological and therapeutic effects of deuterium depletion. She may be contacted via isomlyai@hyd.hu  www.hyd.hu/en

Gábor Somlyai PhD is the CEO of HYD LLC for Cancer Research and Drug Development and president of HYD Pharma Inc., Budapest, Hungary. His speciality is Cancer Research at the submolecular level. He received his PhD in molecular biology in 1988; in 1988 he was also a DFG-scholarship holder at Georg August University in Göttingen for 6 months and  then worked as a postdoctoral fellow at University of Missouri (Columbia, Missouri, USA) in genetic engineering and gene mapping. In 1990 as a senior research fellow at the Hungarian Institute of Oncology he started an examination of the role of naturally occurring deuterium - the heavy isotope of hydrogen - in the regulation of biological, i.e. intracellular molecular processes. In 1993 he established HYD Ltd. with his partners to carry out anticancer research and drug development based on the principle of deuterium depletion. Between 1993 and 1997 he was the scientific director of HYD Ltd., from 1997 he became the CEO of the company. From 2012 he is the president of HYD Pharma Inc. In 2000 his book entitled Defeating cancer! was published in Hungary, and subsequently in Romania, Japan, the USA, in South-Korea and in China. Gábor Somlyai is the author of numerous scientific publications in Hungarian, English and German languages and recognized speaker of international conferences. He may be contacted via gsomlyai@hyd.hu  www.hyd.hu/en